Indivior vs Phibro Animal Health
Phibro Animal Health reported revenue of $1.5 billion in fiscal 2026, 1.2 times Indivior's $1.2 billion in fiscal 2025. Indivior's revenue grew 4.3% in its latest year, and Phibro Animal Health's grew 17.1%. Indivior had an operating margin of 21.1%, against 12.8% at Phibro Animal Health. Free cash flow was −$93 million at Indivior and $10 million at Phibro Animal Health. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.
Side by side
| Indivior | Phibro Animal Health | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Jun 30, 2026 |
| Revenue | $1.2B | $1.5B |
| Revenue growth | 4.3% | 17.1% |
| Revenue growth a year, last 5 years | — | 12.7% |
| Gross margin | 80.2% | 33.8% |
| Operating margin | 21.1% | 12.8% |
| Net margin | 16.9% | 6.6% |
| Free cash flow | −$93M | $10M |
| Free cash flow margin | −7.5% | 0.7% |
| Return on capital | — | — |
| Net debt to EBITDA | 0.5x | — |
| Dividends and buybacks | $11M | $20M |
| Change in diluted share count | −3.8% | 0.7% |
| Last close | $36.28 | $32.96 |
| P/E at the last close | 10.1× | 13.1× |
| Insider trades, last 12 months | bought $229,274, sold $2.8 million | bought $317,700, sold $27.9 million |
| Piotroski F-score | 4 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
IndiviorPhibro Animal Health
Operating margin
Percent of revenue
IndiviorPhibro Animal Health
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
IndiviorPhibro Animal Health
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Indivior and Phibro Animal Health pages.